Q3 2024 Earnings Forecast for Astria Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:ATXS)

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Stock analysts at HC Wainwright dropped their Q3 2024 earnings estimates for shares of Astria Therapeutics in a research note issued on Tuesday, August 13th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.47) per share for the quarter, down from their prior forecast of ($0.42). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for Astria Therapeutics’ Q4 2024 earnings at ($0.53) EPS, FY2024 earnings at ($1.82) EPS, FY2025 earnings at ($1.80) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($1.99) EPS and FY2028 earnings at ($1.68) EPS.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05).

Several other research analysts have also commented on the stock. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday. TD Cowen began coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday. Finally, Oppenheimer upped their target price on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.20.

Astria Therapeutics Trading Up 1.0 %

Shares of NASDAQ ATXS opened at $11.18 on Thursday. The stock has a market capitalization of $613.93 million, a PE ratio of -4.82 and a beta of 0.73. Astria Therapeutics has a 12-month low of $4.26 and a 12-month high of $16.90. The stock’s fifty day simple moving average is $10.12 and its two-hundred day simple moving average is $11.37.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. purchased a new stake in shares of Astria Therapeutics in the first quarter valued at approximately $62,115,000. Perceptive Advisors LLC raised its holdings in Astria Therapeutics by 82.9% in the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock valued at $30,751,000 after buying an additional 1,814,608 shares during the period. Armistice Capital LLC acquired a new stake in shares of Astria Therapeutics during the fourth quarter valued at about $12,119,000. Artal Group S.A. acquired a new stake in Astria Therapeutics in the 1st quarter valued at approximately $12,445,000. Finally, Vivo Capital LLC lifted its stake in Astria Therapeutics by 47.7% during the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock worth $19,067,000 after acquiring an additional 801,528 shares in the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.